Physician profile
Steven Rouse
NPI 1730132937
$995.41
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $705 · 2022: $179 · 2023: $86.68 · 2024: $25.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $176.23 | 2021-2024 | |
| Lilly USA, LLC | $141.01 | 2021-2022 | |
| Novo Nordisk INC | $104.05 | 2021 | |
| Amgen INC. | $90.53 | 2021-2022 | |
| Daiichi Sankyo INC. | $55.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.76 | 2021-2022 | |
| Amarin Pharma, INC. | $46.25 | 2021 | |
| Mylan Specialty L.P. | $40.32 | 2021-2022 | |
| Esperion Therapeutics, INC. | $37.28 | 2021 | |
| Eisai INC. | $32.65 | 2021 | |
| Supernus Pharmaceuticals, INC. | $31.90 | 2021 | |
| Pfizer INC. | $30.80 | 2021 | |
| Nestle Healthcare Nutrition INC. | $26.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.35 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $17.88 | 2021 | |
| Melinta Therapeutics, LLC | $16.89 | 2022 | |
| Abbott Laboratories | $16.57 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.81 | 2021 | |
| Merck Sharp & Dohme LLC | $12.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.